top of page

About
- Our Company
- Our Leadership Team
Science
Products
Pipeline
Newsroom
Contact
Investors
More

Use tab to navigate through the menu items.

Newsroom

All Posts
Publication
News

YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection

YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection

YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection

Dec 8, 2025

YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics

YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics

YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics

Nov 25, 2025

On October 20, 2025, YD Bio Limited (Nasdaq: YDES) proudly held its bell-ringing ceremony at the Nasdaq Stock Exchange, marking the company’s official debut on the international capital market and a new milestone for Taiwan’s biotechnology sector.

On October 20, 2025, YD Bio Limited (Nasdaq: YDES) proudly held its bell-ringing ceremony at the Nasdaq Stock Exchange, marking the company’s official debut on the international capital market and a new milestone for Taiwan’s biotechnology sector.

YD Bio Limited’s Nasdaq Bell-Ringing Ceremony Receives Extensive Media Coverage Across Taiwan and Asia

Oct 28, 2025

YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES

YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES

YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES

Oct 21, 2025

YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities

YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities

YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities

Oct 10, 2025

YD Bio Limited Reports Unaudited Half Year 2025 Financial Results

YD Bio Limited Reports Unaudited Half Year 2025 Financial Results

YD Bio Limited Reports Unaudited Half Year 2025 Financial Results

Oct 1, 2025

DNA Methylation

Investor Relations

Laboratory Developed Tests Services

Exosome Based Therapies

Clinical Trial Drug Distribution

Health Supplements

Privacy Statement

Data Rights Form

21720 23rd Dr. SE, Suite 275,

Bothell, WA 98021, USA

Email: info@ydesgroup.com

Tel: +1 (206) 888-0858

bottom of page